Catatan sumber primer
PenentuHasil topline
Quince Therapeutics: Pembacaan topline Fase 3 NEAT untuk eDSP pada A-T diperkirakan Q1 2026
Perusahaan telah menyelesaikan pendaftaran uji coba Fase 3 NEAT yang penting (total 105 peserta) dan mengonfirmasi bahwa hasil topline akan dilaporkan pada Q1 2026. Uji coba tetap berada di bawah Penilaian Protokol Khusus FDA, dan data positif akan mendukung pengajuan NDA yang direncanakan untuk H2 2026.
Fakta utama
- Diajukan
- 12 Nov 2025, 21.05
- Peristiwa
- Hasil topline
- Arah
- Netral
- Perusahaan
QNCXQuince Therapeutics, Inc.- Aset
- eDSP
- Sumber
- SEC 8-K
- Keyakinan
- Bersumber
- daya
- ~90%
- peserta
- 105
- partisipasi ole
- 100%
- populasi analisis primer
- 83
Kutipan sumber
EX-99.1 2 qncx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results Pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T remains on track with topline results expected in first quarter of 2026 SOUTH SAN FRANCISCO, Calif. – November 12, 2025 – Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development pipeline and reported financial results for the third quarter ended September 30, 2025. Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, said, “Quince remains on track to report